Navigation Links
Hypertension among lower-status employees lingers well into retirement
Date:6/9/2009

than 22,000 non-institutionalized Americans over the age of 50 every two years and includes detailed information on job history, health status, lifestyle and socioeconomic factors.

Using data collected between March 2004 and February 2005, Leigh and Du looked at 7,289 men and women over the age of 65. Their occupations during working years ran the gamut from managers and white-collar professionals to clerical and blue-collar workers. Just a small percentage was still working at the time the data was collected 10 percent of 65-year-olds and 2 percent of 75-year-olds.

The researchers then divided sub-samples by age groups 65 and older, 70 and older and 75 and older as well as by job type, job tenure, gender and physician diagnosis of hypertension. After controlling for variables such as education, race, income, smoking, alcohol consumption, body mass index and co-morbidities, they analyzed the data for statistical associations.

What they found with retirees was consistent with studies of those who are currently employed: higher-status occupations are associated with less hypertension than lower-status occupations.

"For a long time, the conventional wisdom was that the people at the top would be more likely to have hypertension, but just the opposite is true," said Leigh. "Hypertension is more common among people on the lowest rungs of the occupational ladder."

Unlike executives and professionals like architects and engineers, Leigh explained, workers in positions such as sales, administrative support, construction and food preparation have little control over decision-making, are under pressure to get a specified amount of work done in a certain amount of time and may feel inadequate about their positions in the workplace hierarchy. Consequently, their stress levels tend to be higher, which can lead to high blood pressure and, eventually, hypertension.

There were two interesting gender-related distinctions bet
'/>"/>

Contact: Karen Finney
karen.finney@ucdmc.ucdavis.edu
916-734-9064
University of California - Davis - Health System
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Understanding hypertension in African Americans proves elusive
2. Ultra-low-dose aspirin might decrease bleeding severity in portal hypertension
3. Researchers discovery may lead to hypertension treatment
4. Rare genetic mutations protect against hypertension
5. Hypertension treatment effective in reversing vascular damage
6. A single mechanism for hypertension, insulin resistance and immune suppression
7. Blood pressure response to daily stress provides clues for better hypertension treatment
8. Hypertension disparity linked to environment
9. Severe gestational hypertension may protect against testicular cancer
10. Hypertension develops early, silently, in African-American men
11. Hypertension and cholesterol medications present in water released into the St. Lawrence River
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4Jatropha Couple Oil Crop Cultivation Technology Commercially Released 13320 1Jatropha Couple Oil Crop Cultivation Technology Commercially Released 13320 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 13320 3Innovator 26apos 3Bs Studio offers Social Media Strategy Intensive Sept 16 17 2009 53443 1Innovator 26apos 3Bs Studio offers Social Media Strategy Intensive Sept 16 17 2009 53443 2Innovator 26apos 3Bs Studio offers Social Media Strategy Intensive Sept 16 17 2009 53443 3Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 1Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 2Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 3Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 4Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on 4809 5